This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Torrent cleared for semaglutide launch in India, defeats Novo Nordisk's injunction bid

By Freny Patel ( March 25, 2026, 03:33 GMT | Insight) -- Torrent Pharmaceuticals has been cleared to launch its semaglutide product after an Indian court found no infringement of Novo Nordisk’s formulation patent. The Delhi High Court stressed claim scope limits, permitting sales subject to compliance and product testing.In a legal tussle with global healthcare giant Novo Nordisk, India’s Torrent Pharmaceuticals has secured the right to proceed with launching its indigenous semaglutide product under an interim arrangement ordered by the Delhi High Court....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login